News
Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.
7h
AI4Beginners on MSNModernizing Biotech Compliance: Inside the Transformation of Enterprise Validation SystemsThat’s the environment where Venkatesh Kanneganti, a senior IEEE member, and a seasoned Quality Assurance and validation ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...
A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...
Gilead Sciences, Inc. (NASDAQ:GILD) is one of Goldman Sachs’ top healthcare stock picks. On July 10, the company announced it ...
Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...
"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...
Massachusetts AG Campbell secures $1.6 million for the state's Medicaid in a settlement with Gilead over illegal kickbacks ...
The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...
Gilead Sciences Inc. doesn’t have to face a fired employee’s claim that its response to a colleague’s false sexual harassment ...
Arcellx, Inc. advances anito-cel CAR-T therapy for relapsed/refractory multiple myeloma. Click for ACLX pivotal trials, FDA ...
12h
allAfrica.com on MSNSA gets R520m to buy the twice-a-year anti-HIV jab... but there’s a snagSouth Africa has accepted an offer of just over $29 million (about R520 million) from the Global Fund to Fight Aids, TB and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results